Literature DB >> 18181563

Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy.

Tomás Vitha1, Vojtech Kubícek, Petr Hermann, Luce Vander Elst, Robert N Muller, Zvonimir I Kolar, Hubert T Wolterbeek, Wouter A P Breeman, Ivan Lukes, Joop A Peters.   

Abstract

Lanthanide complexes of DOTA derivatives 2a (BPAMD) and 2b (BPAPD), having a monoamide pendant arm with a bis(phosphonate) moiety, were comparatively tested for application in MRI, radiotherapy, and bone pain palliation. (1)H, (31)P, and (17)O NMR spectroscopy show that they are nine-coordinated, with one water molecule in the first coordination sphere of the Ln(III) ion. The bis(phosphonate) moieties are not coordinated to the lanthanide and predominantly mono- and diprotonated at physiological pH. The parameters governing the longitudinal relaxivities of the Gd complexes are similar to those of other monoamides of DOTA reported in the literature. Upon adsorption on hydroxyapatite, the relaxivities at 20 MHz and 25 degrees C of Gd-2a and Gd-2b were 22.1 and 11 s(-1) mM(-1), respectively. An in vivo gamma-ray imaging study showed that the (177)Lu complexes of 2a and 2b have a high affinity for bones, particularly for growth plates and teeth with a prolonged retention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18181563     DOI: 10.1021/jm7012776

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  In vivo characterization of a smart MRI agent that displays an inverse response to calcium concentration.

Authors:  Ilgar Mamedov; Santiago Canals; Jörg Henig; Michael Beyerlein; Yusuke Murayama; Hermann A Mayer; Nikos K Logothetis; Goran Angelovski
Journal:  ACS Chem Neurosci       Date:  2010-10-20       Impact factor: 4.418

2.  An osteoclast-targeting agent for imaging and therapy of bone metastasis.

Authors:  Wei Liu; Asghar Hajibeigi; Mai Lin; Cynthia L Rostollan; Zoltan Kovacs; Orhan K Oz; Xiankai Sun
Journal:  Bioorg Med Chem Lett       Date:  2008-07-27       Impact factor: 2.823

3.  PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study.

Authors:  Marco Fellner; Richard P Baum; Vojtech Kubícek; Petr Hermann; Ivan Lukes; Vikas Prasad; Frank Rösch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

Review 4.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

5.  Bone-seeking TRAP conjugates: surprising observations and their implications on the development of gallium-68-labeled bisphosphonates.

Authors:  Johannes Notni; Jan Plutnar; Hans-Jürgen Wester
Journal:  EJNMMI Res       Date:  2012-03-30       Impact factor: 3.138

6.  Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.

Authors:  Kazuma Ogawa; Atsushi Ishizaki; Kenichiro Takai; Yoji Kitamura; Tatsuto Kiwada; Kazuhiro Shiba; Akira Odani
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

7.  (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

Authors:  Ralf Bergmann; Marian Meckel; Vojtěch Kubíček; Jens Pietzsch; Jörg Steinbach; Petr Hermann; Frank Rösch
Journal:  EJNMMI Res       Date:  2016-01-16       Impact factor: 3.138

Review 8.  Empowering the Medicinal Applications of Bisphosphonates by Unveiling their Synthesis Details.

Authors:  Jéssica S Barbosa; Susana Santos Braga; Filipe A Almeida Paz
Journal:  Molecules       Date:  2020-06-18       Impact factor: 4.411

Review 9.  Bisphosphonate conjugation for bone specific drug targeting.

Authors:  Kristen B Farrell; Alexander Karpeisky; Douglas H Thamm; Shawn Zinnen
Journal:  Bone Rep       Date:  2018-07-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.